News
Investors
Careers
Contacts
About Us
Our Mission & Vision
The Zevra Story
Leadership
Board of Directors
What We Do
Partnering
Patients & Caregivers
Clinical Trials
Expanded Access Policy
Niemann-Pick Disease Type C
Urea Cycle Disorders
Vascular Ehlers-Danlos
Sleep Disorders
Our Products
MIPLYFFA®
OLPRUVA®
AZSTARYS®
Our Pipeline
Pipeline
Clinical Trials
Publications & Presentations
Medical Literature
Medical Information
Investigator-Initiated Studies
News
Investors
Careers
Contacts
Home
>
Latest
>
Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers
Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers